title: Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis.
abstract: BACKGROUND
  The purpose of the present paper was to investigate the factors possibly involved in the failure of pegylated interferon (Peg IFN) plus ribavirin treatment at standard dosage in hepatitis C virus (HCV) 1b patients, with chronic hepatitis.
  
  
  METHODS
  A fully screened population of 40 virological non-responders (NR) to combined antiviral therapy was selected and matched, 1:1, with a similar cohort of end-therapy virological responders (R).
  
  
  RESULTS
  Waist circumference, glucose metabolic impairment, body mass index, non-genetic iron overload, steatosis and fibrosis severity and, finally, arterial hypertension were statistically more frequent in the NR group on Peg IFN plus ribavirin. Increased waist circumference was the strong independent predictor of therapeutical failure. Interestingly, the concomitant presence of cofactors was more significantly represented in NR, whereas in the R cohort this association was found in a few cases only.
  
  
  CONCLUSIONS
  Insulin-resistance syndrome could contribute to non-response in treated chronic HCV patients, suggesting the presence of dysmetabolic factors that frequently cluster in a critical combination.
authors.affiliation: Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy. tarantin@unina.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Tarantino
authors.forename: Paolo
authors.initials: P
authors.lastname: Conca
authors.forename: Paolo
authors.initials: P
authors.lastname: Sorrentino
authors.forename: Manuela
authors.initials: M
authors.lastname: Ariello
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D015992:Body Mass Index; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use; D012307:Risk Factors; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b